Perioperative Pembrolizumab Head and Neck Cancer Treatment
- What: The FDA approved Arexvy, a respiratory syncytial virus (RSV) vaccine, for adults aged 60 years and older.
- Why it Matters: RSV causes notable illness and hospitalization in older adults, and this is the first widely available vaccine to prevent it.
- What's Next: Increased vaccine availability and ongoing monitoring of effectiveness and safety.
RSV Vaccine Approved for Older adults: A Breakthrough in Respiratory Protection
Table of Contents
Understanding RSV and Why It’s a Threat to Seniors
Respiratory Syncytial Virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Before the availability of a vaccine, RSV was estimated to cause approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years of age and older in the United States.
The virus spreads through close contact with infected individuals, frequently enough via respiratory droplets produced during coughing or sneezing. older adults are particularly vulnerable due to age-related decline in immune function and the presence of underlying health conditions like heart disease or chronic lung disease.
The Arexvy Vaccine: How It Works
Arexvy, manufactured by GSK, is a recombinant subunit vaccine. This means it doesn’t contain a live virus.Instead, it uses a stabilized form of the RSV fusion (F) protein to trigger an immune response. The F protein is crucial for the virus to enter cells, and by targeting it, the vaccine prepares the body to fight off RSV infection.
clinical trials,as reported in the New England Journal of Medicine,Volume 393,Issue 11 (September 18,2025),demonstrated approximately 82.6% efficacy in preventing RSV-associated lower respiratory tract disease (LRTD) in adults 60 years and older. The trials also showed a 94.1% efficacy in preventing severe LRTD.
Key Findings from the RSV Vaccine Trials
| Outcome | Efficacy (%) |
|---|---|
| RSV-associated Lower Respiratory Tract Disease (LRTD) | 82.6 |
| Severe RSV-associated LRTD | 94.1 |
The trials involved over 20,000 participants and were conducted across multiple sites. While the vaccine showed strong efficacy, it’s significant to note that, as with any vaccine, it’s not 100% effective. Some vaccinated individuals may still contract RSV, but they are likely to experience milder symptoms.
Who Should Get the RSV Vaccine?
The Centers for Disease Control and prevention (CDC) recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making with their healthcare provider. This means a discussion about the individual’s risk factors, health status, and preferences is crucial.
Individuals with certain medical conditions, such as chronic heart or lung disease, diabetes, or a weakened immune system, are at higher risk of severe RSV illness and may benefit most from vaccination. however, even healthy older adults can experience significant complications from RSV, making vaccination a worthwhile consideration.
Potential Side Effects and Safety Considerations
The most commonly reported side effects from the Arexvy vaccine in clinical trials were pain at the injection site, fatigue, muscle aches, headache, and joint pain. These side effects were